Angiogenesis inhibition and lung-cancer therapy

Affiliations

¹ Sheba Medical Center, Institute of Pulmonology, Tel Hashomer, Ramat Gan, Israel.
² Institute of Oncology, Tel Hashomer, Ramat Gan, Israel.
³ Yale Cancer Center, Section of Medical Oncology, New Haven, CT 06520, USA. Electronic address: roy.herbst@yale.edu.

Comment

Amir Onn et al. Lancet Oncol. 2014 Feb.

. 2014 Feb;15(2):124-5.

doi: 10.1016/S1470-2045(14)70010-5.

¹ Sheba Medical Center, Institute of Pulmonology, Tel Hashomer, Ramat Gan, Israel.
² Institute of Oncology, Tel Hashomer, Ramat Gan, Israel.
³ Yale Cancer Center, Section of Medical Oncology, New Haven, CT 06520, USA. Electronic address: roy.herbst@yale.edu.

No abstract available

Comment on

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group. Reck M, et al. Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9. Lancet Oncol. 2014. PMID: 24411639 Clinical Trial.